#1 Clinical Trials Search in Europe

Gsk4004280

This article discusses a clinical trial investigating the use of GSK4004280, a new oral capsid inhibitor, in the treatment of HIV-1 infections. The study aims to assess the drug’s antiviral effects, safety, tolerability, and pharmacokinetics in treatment-naïve adults with HIV-1. This research is an important step in developing new therapeutic options for people living with HIV.

Table of Contents

What is GSK4004280?

GSK4004280 is a new medication being developed to treat HIV-1 infections. It is currently undergoing clinical trials to test its effectiveness and safety in humans[1]. HIV-1 is the most common type of Human Immunodeficiency Virus, which attacks the body’s immune system and can lead to AIDS if left untreated.

How Does GSK4004280 Work?

GSK4004280 is classified as a capsid inhibitor. The capsid is a protein shell that surrounds the genetic material of the HIV virus. By targeting this capsid, the drug aims to interfere with the virus’s ability to replicate and spread in the body[1]. This approach is different from many existing HIV treatments, which often target other parts of the virus’s life cycle.

Clinical Trial Details

The clinical trial for GSK4004280 is a Phase 2 study, which means it’s testing the drug’s effectiveness and safety in a larger group of people after initial safety has been established[1]. Here are some key details about the trial:

  • It’s a randomized, double-blind, placebo-controlled trial. This means participants are randomly assigned to either receive the drug or a placebo, and neither the participants nor the researchers know who is getting which until the end of the study[1].
  • The main goal is to evaluate how well GSK4004280 reduces the amount of HIV-1 virus in the blood (known as viral load) over a 10-day period[1].
  • The study will also look at the safety and tolerability of the drug, as well as how it’s processed by the body (pharmacokinetics)[1].

Who Can Participate in the Trial?

The trial is looking for specific types of participants. Here are some of the main criteria:

  • Adults aged 18 to 65 years[1]
  • People who are generally healthy apart from their HIV-1 infection[1]
  • Individuals who have never received treatment for HIV before (treatment-naïve)[1]
  • Those with a certain level of HIV in their blood and a specific count of CD4+ T-cells (a type of immune cell affected by HIV)[1]

There are also several conditions that would prevent someone from participating, such as pregnancy, certain other infections, or specific health issues[1].

What to Expect During the Trial

If you participate in the trial, here’s what you might expect:

  1. You’ll be randomly assigned to receive either GSK4004280 or a placebo for 10 days[1].
  2. During this time, you’ll need to take the medication orally (by mouth) as directed[1].
  3. You’ll have regular check-ups and blood tests to monitor your viral load and overall health[1].
  4. After the 10-day period, you’ll start on a standard HIV treatment regimen, regardless of whether you received GSK4004280 or placebo[1].
  5. You’ll continue to be monitored for a total of 39 days to ensure your safety and to gather more data on the drug’s effects[1].

Potential Benefits and Risks

As with any clinical trial, there are potential benefits and risks to consider:

Potential Benefits:

  • You may receive a new treatment that could be more effective than existing options[1].
  • You’ll receive close medical monitoring throughout the trial[1].
  • You’ll contribute to the advancement of HIV treatment research[1].

Potential Risks:

  • The drug may cause side effects, some of which may be serious or unexpected[1].
  • The treatment may not be effective for you, especially if you receive the placebo[1].
  • Participation in the trial may require significant time commitment and multiple medical visits[1].

It’s important to discuss these potential benefits and risks with your healthcare provider and the research team before deciding to participate in any clinical trial.

Aspect Details
Drug Name GSK4004280
Drug Type Oral capsid inhibitor
Study Phase Phase 2
Main Objective Evaluate antiviral activity over 10 days in treatment-naïve HIV-1 infected adults
Secondary Objectives Assess safety, tolerability, and pharmacokinetics; Determine relationship between drug exposure and HIV-1 RNA changes
Study Design Randomized, double-blind, placebo-controlled trial
Treatment Duration 10 days of GSK4004280 or placebo, followed by standard HIV treatment through Day 39
Key Inclusion Criteria Adults 18-65 years, HIV-1 infected, treatment-naïve, CD4+ count ≥200 cells/µL, HIV-1 RNA ≥3000 copies/mL
Primary Endpoint Maximum change in plasma HIV-1 RNA from baseline through Day 11

FAQ

  • What is GSK4004280? GSK4004280 is an oral capsid inhibitor being studied as a potential treatment for HIV-1 infections. It is a new type of drug that targets the capsid, which is a protein shell that protects the virus's genetic material.
  • What is the main goal of this clinical trial? The main goal of this trial is to evaluate the antiviral activity of GSK4004280 when given as monotherapy for 10 days in HIV-1 infected adults who have not received previous treatment.
  • Who can participate in this study? The study is open to adults aged 18-65 who have documented HIV-1 infection, are treatment-naïve (have not received HIV treatment before), have a CD4+ T-cell count of 200 cells/µL or higher, and meet other specific health criteria.
  • How long does the treatment last in this trial? Participants receive GSK4004280 or a placebo for 10 days, followed by standard HIV treatment (combination antiretroviral therapy) through Day 39 of the study.
  • What are the main things researchers will be looking at in this study? Researchers will primarily look at the maximum change in HIV-1 RNA levels in the blood from the start of treatment to Day 11. They will also assess the safety and tolerability of GSK4004280, study its pharmacokinetics (how the drug moves through the body), and examine the relationship between drug exposure and changes in HIV-1 RNA levels.

Ongoing Clinical Trials on Gsk4004280

  • Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Capsid Inhibitor: A type of drug that targets the capsid, which is a protein shell that surrounds and protects the genetic material of HIV. By interfering with the capsid, these drugs aim to prevent the virus from reproducing.
  • Monotherapy: Treatment using a single drug, in this case, GSK4004280 alone, without other HIV medications.
  • Treatment-Naïve: Refers to individuals who have never received treatment for their HIV infection before.
  • CD4+ T-cell count: A measure of the number of CD4 T cells in the blood. These cells are important for the immune system and are targeted by HIV. A higher count generally indicates a healthier immune system.
  • Plasma HIV-1 RNA: The amount of HIV genetic material in the blood, often referred to as viral load. It's used to measure how much virus is present and how well treatment is working.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Antiretroviral therapy: A combination of medications used to treat HIV infection by suppressing the virus and slowing the progression of the disease.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it's related to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-gsk4004280-and-gsk4011499-in-adults-with-hiv-infections/